Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
METHYLPHENIDATE hydrochloride extended-release tablets USP. These highlights do not include all the information needed to use methylphenidate hydrochloride extended-release tablets USP safely and effectively. See full prescribing information for METHYLPHENIDATE hydrochloride extended-release tablets USP. METHYLPHENIDATE hydrochloride extended-release tablets USP, for oral use, CII Initial U.S. Approval: 2000
Medication labelWhy this: Advisory · dailymed-prescription
Methylphenidate hydrochloride extended-release tablets are indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in patients aged 6 to 65 years old. Limitations of Use The use of methylphenidate hydrochloride extended-release tablets is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage [see Warnings and Precautions ( 5.7), and Use in Specific Populations ( 8.4)].
- generic_name
- methylphenidate hydrochloride
- product_names
- Methylphenidate hydrochloride
- ndc
- 51407-924, 51407-925, 51407-926, 51407-927, 51407-927-01, 51407-924-01, 51407-925-01, 51407-926-01
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en